The purpose of the Animal Genomics Shared Resource (AGS) is to create (and through cryopreservation, maintain) transgenic and knockout models for human diseases including cancer. The specific objectives are: 1) Provide consultation on transgene and targeting construct design;2) Introduce DNA into zygotes or embryonic stem cells;3) Create founder animals or chimeras that incorporate the desired, DNA addition or change;and 4) Cryopreserve mouse embryos for cost-effective, long-term storage of genetically engineered mice. The Transgenic mouse service was created in 1989. The ability to create knockout mice was added in 1997. Cryopreservation of mouse embryos has been performed since 2000. The creation of novel mouse strains, either by transgenesis or homologous recombination, allows many members of the Yale Cancer Center (YCC), to determine the normal function of genes and how perturbation of that function can result in aberrant development or diseases such as cancer. Investigators can use AGS to create direct analogs of mutations involved in human disease, thus providing models that can be studied in a way that human subjects cannot. The ability to create such induced mutants allows investigators to effectively use mouse genetics to dissect and analyze complicated developmental pathways, biochemical processes, and biomolecular interactions in a mammal to a level previously unattainable before such technology existed. This enables researchers to investigate biological processes at a far deeper level than in vitro methods such as biochemistry or cell culture will allow, and through the appearance of novel phenotypes resulting from induced mutations, discover new relationships between these processes and pathways. Cryopreservation of mouse strains allows investigators to more efficiently utilize their financial resources in research while maintaining valuable strains for future use. The YCC AGS produces 40-60 transgenic mouse strains/year, and creates 15-20 new targeted mutant mouse models/year. Animal Genomics Services has been a shared resource of the YCC since 1989. AGS moved into new space designed specifically for their use with the completion of The Anylan Center building in 2002. Twenty-eight YCC investigators used AGS in 2005 for a total of approx. 62% of all usage of the resource. All YCC usage during 2005 was from peer-reviewed scientists from 7 of 8 YCC Research Programs

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-33
Application #
8312358
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
33
Fiscal Year
2011
Total Cost
$179,407
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083

Showing the most recent 10 out of 675 publications